Live Analyst Rating Changes 22483 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Adam Maeder
PIPR

Adam Maeder

Piper Sandler
Wall Street Analyst
★★☆☆☆
#2380
on 13Foresight · ranked by our own returns
50%
Success Rate
+1.7%
Average Return
18 of 36 calls profitable · -3.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 50% of Adam Maeder's ratings turned a profit when each position was held for 1 year — averaging +1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

74 Buy 21 Hold 0 Sell
Adam's Stock Coverage 18 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
RMD
Resmed
 Aug 07, 2026 HOLD Buy
+4.8% avg upside
27 analysts
$225.00
2.28% Upside
 +0.0% ·
GKOS
Glaukos
 Aug 07, 2026 BUY Strong Buy
-8.0% avg upside
21 analysts
$195.00
7.52% Upside
 +0.0% ·
RXST
RxSight
 Aug 06, 2026 HOLD Hold
+35.9% avg upside
13 analysts
$10.00
52.22% Upside
 +6.7% ·
SGHT
Sight Sciences
 Aug 06, 2026 BUY Buy
+16.1% avg upside
13 analysts
$9.00
16.81% Upside
 +0.0% ·
NYXH
Nyxoah
 Aug 06, 2026 BUY Strong Buy
+814.8% avg upside
12 analysts
$6.00
279.73% Upside
 +12.2% ·
INSP
Inspire Medical Systems
 Aug 04, 2026 HOLD Buy
+41.8% avg upside
21 analysts
$60.00
0.55% Upside
 -6.0% ·
NSPR
InspireMD
 Jul 31, 2026 BUY Strong Buy
+378.8% avg upside
8 analysts
$3.00
274.86% Upside
 +10.8% ·
EW
Edwards Lifesciences
 Jul 24, 2026 BUY Strong Buy
+9.6% avg upside
34 analysts
$101.00
9.70% Upside
 +12.9% ·
STAA
Staar Surgical
 Jul 17, 2026 HOLD Hold
+35.4% avg upside
16 analysts
$33.00
31.30% Upside
 -8.4% ·
ABT
Abbott Laboratories
 Jul 17, 2026 BUY Strong Buy
+6.3% avg upside
36 analysts
$118.00
8.68% Upside
 +7.9% ·
ISRG
Intuitive Surgical
 Jul 17, 2026 BUY Strong Buy
+23.3% avg upside
36 analysts
$470.00
19.50% Upside
 +15.8% ·
LIVN
LivaNova
 Jun 23, 2026 BUY Strong Buy
+6.5% avg upside
15 analysts
$87.00
13.69% Upside
 -2.3% ·
STXS
Stereotaxis
 May 13, 2026 BUY Strong Buy
+195.8% avg upside
7 analysts
$3.50
143.12% Upside
 -22.2% ·
TCMD
Tactile Systems Technology
 May 05, 2026 BUY Strong Buy
+40.5% avg upside
8 analysts
$42.00
44.13% Upside
 +21.2% ·
STIM
Neuronetics
 Apr 07, 2026 BUY Strong Buy
+164.1% avg upside
7 analysts
$3.00
38.17% Upside
 +50.6% ·
RBOT
Vicarious Surgical
 Aug 13, 2025 HOLD Buy
+18626.3% avg upside
6 analysts
$7.00
10652.72% Upside
 -99.2% ·
NSP
Insperity
 Apr 09, 2020 BUY Hold
+5.8% avg upside
6 analysts
$74.00
44.48% Upside
 +116.9% ·
TSE:CNVI
Conavi Medical
 Dec 23, 2019 BUY Buy
+759.1% avg upside
4 analysts
$2.09
1062.66% Upside
 · ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Adam Maeder — Frequently Asked Questions
How accurate are Adam Maeder's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Adam's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, or -3.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Adam ranked on 13Foresight?
Adam Maeder is currently ranked #2380 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Adam cover?
Adam most recently has ratings on RMD, GKOS, RXST, SGHT, NYXH, INSP, NSPR, EW, STAA, ABT, ISRG, LIVN and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.